178 related articles for article (PubMed ID: 35203024)
1. Comprehensive analysis of TAMs marker genes in glioma for predicting prognosis and immunotherapy response.
Zhao Z; Wang Z; Wu Y; Liao D; Zhao B
Mol Immunol; 2022 Apr; 144():78-95. PubMed ID: 35203024
[TBL] [Abstract][Full Text] [Related]
2. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
[TBL] [Abstract][Full Text] [Related]
3. ITGB2 as a prognostic indicator and a predictive marker for immunotherapy in gliomas.
Xu H; Zhang A; Han X; Li Y; Zhang Z; Song L; Wang W; Lou M
Cancer Immunol Immunother; 2022 Mar; 71(3):645-660. PubMed ID: 34313821
[TBL] [Abstract][Full Text] [Related]
4. IL4I1 in M2-like macrophage promotes glioma progression and is a promising target for immunotherapy.
Ye F; Wang L; Li Y; Dong C; Zhou L; Xu J
Front Immunol; 2023; 14():1338244. PubMed ID: 38250074
[TBL] [Abstract][Full Text] [Related]
5. Single cell RNA sequencing reveals differentiation related genes with drawing implications in predicting prognosis and immunotherapy response in gliomas.
Zhou Z; Wei J; Yang Z; Bao Y; Jiang W; Lu B; Wang W; Li L
Sci Rep; 2022 Feb; 12(1):1872. PubMed ID: 35115572
[TBL] [Abstract][Full Text] [Related]
6. Tumor-associated macrophages related signature in glioma.
Wang LJ; Xue Y; Lou Y
Aging (Albany NY); 2022 Mar; 14(6):2720-2735. PubMed ID: 35332109
[TBL] [Abstract][Full Text] [Related]
7. Pyroptosis: a novel signature to predict prognosis and immunotherapy response in gliomas.
He G; Chen Z; Zhuo S; Tang J; Hao W; Yang K; Yang C
Hum Cell; 2022 Nov; 35(6):1976-1992. PubMed ID: 36129672
[TBL] [Abstract][Full Text] [Related]
8. Immunogenic cell death-related risk signature predicts prognosis and characterizes the tumour microenvironment in lower-grade glioma.
Cai J; Hu Y; Ye Z; Ye L; Gao L; Wang Y; Sun Q; Tong S; Yang J; Chen Q
Front Immunol; 2022; 13():1011757. PubMed ID: 36325335
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of a nine-gene signature in glioma patients based on tumor-associated macrophages expression profiling.
Shan X; Zhang C; Wang Z; Wang K; Wang J; Qiu X; Jiang T; Yang P
Clin Immunol; 2020 Jul; 216():108430. PubMed ID: 32325251
[TBL] [Abstract][Full Text] [Related]
10.
Qu S; Liu J; Wang H
Front Immunol; 2021; 12():648416. PubMed ID: 33889156
[TBL] [Abstract][Full Text] [Related]
11. Six Immune Associated Genes Construct Prognostic Model Evaluate Low-Grade Glioma.
Tan YQ; Li YT; Yan TF; Xu Y; Liu BH; Yang JA; Yang X; Chen QX; Zhang HB
Front Immunol; 2020; 11():606164. PubMed ID: 33408717
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive analysis of m
Zhao K; Li W; Yang Y; Hu X; Dai Y; Huang M; Luo J; Zhang K; Zhao N
Front Immunol; 2022; 13():955848. PubMed ID: 36203569
[TBL] [Abstract][Full Text] [Related]
13. Weighted gene correlation network analysis identifies microenvironment-related genes signature as prognostic candidate for Grade II/III glioma.
Li Y; Deng G; Zhang H; Qi Y; Gao L; Tan Y; Hu P; Wang Y; Liu B; Chen Q
Aging (Albany NY); 2020 Nov; 12(21):22122-22138. PubMed ID: 33186124
[TBL] [Abstract][Full Text] [Related]
14. Ferroptosis-related gene signature correlates with the tumor immune features and predicts the prognosis of glioma patients.
Hu Y; Tu Z; Lei K; Huang K; Zhu X
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34726238
[TBL] [Abstract][Full Text] [Related]
15. ARL3 is downregulated and acts as a prognostic biomarker in glioma.
Wang Y; Zhao W; Liu X; Guan G; Zhuang M
J Transl Med; 2019 Jun; 17(1):210. PubMed ID: 31234870
[TBL] [Abstract][Full Text] [Related]
16. Ferroptosis-related gene signature predicts prognosis and immunotherapy in glioma.
Wan RJ; Peng W; Xia QX; Zhou HH; Mao XY
CNS Neurosci Ther; 2021 Aug; 27(8):973-986. PubMed ID: 33969928
[TBL] [Abstract][Full Text] [Related]
17. Optimization of cancer immunotherapy through pyroptosis: A pyroptosis-related signature predicts survival benefit and potential synergy for immunotherapy in glioma.
Zeng Y; Cai Y; Chai P; Mao Y; Chen Y; Wang L; Zeng K; Zhan Z; Xie Y; Li C; Zhan H; Zhao L; Chen X; Zhu X; Liu Y; Chen M; Song Y; Zhou A
Front Immunol; 2022; 13():961933. PubMed ID: 35990696
[TBL] [Abstract][Full Text] [Related]
18. Deciphering the role of QPCTL in glioma progression and cancer immunotherapy.
Liu Y; Lu S; Sun Y; Wang F; Yu S; Chen X; Wu LL; Yang H; Shi Y; Zhao K
Front Immunol; 2023; 14():1166377. PubMed ID: 37063864
[TBL] [Abstract][Full Text] [Related]
19. Mutational profiling of low-grade gliomas identifies prognosis and immunotherapy-related biomarkers and tumour immune microenvironment characteristics.
Lin WW; Ou GY; Zhao WJ
J Cell Mol Med; 2021 Nov; 25(21):10111-10125. PubMed ID: 34597473
[TBL] [Abstract][Full Text] [Related]
20. A Novel Immune Gene-Related Prognostic Score Predicts Survival and Immunotherapy Response in Glioma.
Luo X; Wang Q; Tang H; Chen Y; Li X; Chen J; Zhang X; Li Y; Sun J; Han S
Medicina (Kaunas); 2022 Dec; 59(1):. PubMed ID: 36676646
[No Abstract] [Full Text] [Related]
[Next] [New Search]
